CLClinicLens

Nephrology

FDA Adds Kidney Injury Warning to OTC Weight-Loss Drug Orlistat | ClinicLens

The US Food and Drug Administration (FDA) approved labeling changes for the over-the-counter (OTC) weight-loss drug orlistat to warn of acute kidney injury risks.

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.